Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06311578 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Johnson & Johnson Enterprise Innovation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 10
- Study locations
NCT06311578 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by Johnson & Johnson Enterprise Innovation. The registered enrollment target is 96 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower). The trial reports 10 study locations across 6 states.
The verdict
NCT06311578, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by Johnson & Johnson Enterprise Innovation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Conditions Studied
Interventions
- DRUG Cetrelimab
- DRUG JNJ-87704916
Study Locations (10)
Other
- Gustave Roussy - Villejuif
- Hosp Univ Vall D Hebron - Barcelona
- Hosp Univ Fund Jimenez Diaz - Madrid
- Hosp Univ Hm Sanchinarro - Madrid
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- UPMC Cancer Centers - Pittsburgh
New York
- NYU Langone Health - New York
Texas
- MD Anderson Cancer Center - Houston
Ontario
- Toronto General Hospital - Toronto
Quebec
- Centre Hospitalier de l'Universite de Montreal - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2032-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06311578
The ClinicalTrials.gov registry entry for NCT06311578 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower). The listed sponsor is Johnson & Johnson Enterprise Innovation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Cetrelimab is the first listed.
NCT06311578 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Other, Pennsylvania, New York.
Frequently Asked Questions
What is clinical trial NCT06311578 about?
NCT06311578 is a clinical study titled "A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors". The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
What is the current status of trial NCT06311578?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2024-04-10. Estimated completion is 2032-08-26.
What conditions does trial NCT06311578 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT06311578?
The interventions under investigation include: Cetrelimab (DRUG), JNJ-87704916 (DRUG).
Who is sponsoring clinical trial NCT06311578?
This trial is sponsored by Johnson & Johnson Enterprise Innovation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06311578 being conducted?
This trial has 10 study locations across New York, Pennsylvania, Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.